Roivant Sciences Ltd.
ROIV
Rank in Stocks
#983
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Share Price
$33.73
Last synced: 2026-07-31
Market Cap
$24.37B
Change (1 day)
-2.28%
Change (1 year)
95.44%
Country
GB
Trade Roivant Sciences Ltd. (ROIV)
Category
Healthcare
EPS for Roivant Sciences Ltd. (ROIV)
EPS as of June 2026 TTM: $-0.38
According to Roivant Sciences Ltd. latest financial reports and stock price the company's current EPS (TTM) is $-0.38. At the end of 2024 the company had a EPS of $5.55 an increase over its 2023 EPS that were of $-1.42.
EPS history for Roivant Sciences Ltd. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
